Education

Tocilizumab is a recombinant humanized monoclonal IL-6 receptor antibody indicated for the treatment of severe rheumatoid arthritis and other inflammatory disorders.Following clinical observation from China, a series of Italian studies have been carried out to evaluate the off-label use of tocilizumab in COVID-19 patients.
The European Journal of Internal Medicine (EJIM) has recently accepted for publication three articles on the off-label use of tocilizumab in patients with severe COVID-19.

Visit the Information Center available through our publisher Elsevier, to find the most relevant research on the Novel Coronavirus (COVID-19), freely available here.

FDIME Announces Research Grants in 2020

The Foundation for the Development of Internal Medicine in Europe (FDIME) is offering Research Grants to Young Internists (up to age 38 yrs) to study in:
Research projects including all fields of General Internal Medicine, particularly polymorbidity and other common Internal Medicine conditions.

For details check the FDIME Research Grants webpage at www.fdime.org
OR

Download the Internal Medicine Grant Announcement and Application Form

For further information: